CureDuchenne Ventures

The medical ID bracelet has a customizable profile with emergency information, a silicone design, and a snap-and-tuck fastener. It is free to individuals in the United States living with Duchenne, though shipping costs apply.

CureDuchenne says it has worked with biotech and pharmaceutical companies for a decade to accelerate treatments for Duchenne muscular dystrophy.

The page says combining antisense oligonucleotides to skip multiple exons may offer a treatment approach for a significant number of people with Duchenne.

CureDuchenne’s chief scientific advisor, Dr. Mike Kelly, reviews a paper by Annemieke Aartsma-Rus and other researchers and explains its findings.

To assess safety and efficacy of deflazacort (DFZ) and prednisone (PRED) vs placebo in Duchenne muscular dystrophy (DMD).

Santhera Pharmaceuticals announced that Emory University scientists and partner ReveraGen Biopharma published new data on the molecular mode of action.

The page describes research and support programs as offering hope to thousands worldwide.

Committed to improving the lives of everyone affected by Duchenne through accelerating research, improving care and empowering the community.

The company thanks its partners and sponsors for helping people affected by Duchenne.

Headquarters100 Bayview Circle, Ste 5600Newport Beach, CA 92660 +1 949-872-2552info@cureduchenne.com

CureDuchenne’s mission is to cure Duchenne muscular dystrophy (DMD), and its venture philanthropy model funds research, early diagnosis, and treatment.

CureDuchenne’s privacy policy describes information it collects, including through its website, and how it uses and shares that information.